Interleukin-12 receptor subunit beta-2 (IL-12RB2) (IL-12RB2)

Interleukin-12 receptor subunit beta-2 (IL-12RB2) is a type I transmembrane protein that serves as the essential signaling component of the high-affinity interleukin-12 (IL-12) receptor complex [1, 10]. It forms a heterodimer with the IL-12Rβ1 subunit to bind IL-12, a cytokine critical for bridging innate and adaptive immunity [5, 9]. Upon ligand binding, IL-12Rβ2 recruits and activates Janus kinase 2 (JAK2), leading to the phosphorylation of STAT4 and subsequent induction of interferon-gamma (IFN-γ) production and T helper 1 (Th1) cell differentiation [2, 10]. The expression of IL-12Rβ2 is highly regulated and restricted primarily to activated T cells and natural killer (NK) cells, making it a key gatekeeper for Th1-mediated immune responses [1, 5]. Dysregulation of IL-12Rβ2 is implicated in various pathologies; its overexpression is associated with autoimmune and inflammatory diseases like Crohn's disease and multiple sclerosis, while its deficiency or silencing is linked to increased susceptibility to intracellular infections and B-cell malignancies [4, 6, 12]. Therapeutic strategies often target the IL-12 pathway using monoclonal antibodies like ustekinumab to treat inflammatory conditions, while recombinant IL-12 and its analogs are explored in oncology to enhance anti-tumor immunity [1, 11].

Other names

IL-12 receptor beta-2IL-12RB2Interleukin-12 receptor subunit beta-2IL-12R subunit beta-2Interleukin-12 receptor beta-2 chain

Inhibition of IL-12 signaling through ligand neutralization (e.g., ustekinumab) or direct receptor activation (e.g., rhIL-12) to modulate Th1-mediated immune responses.